Navigation Links
Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
Date:7/4/2008

BASINGSTOKE, England and PHILADELPHIA, July 4 /PRNewswire-FirstCall/ -- Shire Limited (LSE:SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce second quarter 2008 earnings on Thursday 31 July 2008

Results press release will be issued at: 12:00 BST / 07:00 EDT

Investor meeting and conference call time: 14:30 BST / 09:30 EDT

Investor & Analyst meeting and conference call:

Angus Russell, Chief Executive Officer, Graham Hetherington, Chief Financial Officer, Mike Cola, President, Specialty Pharmaceuticals and Sylvie Grégoire, President, Human Genetic Therapies will host the investor and analyst meeting and conference call at 14:30 BST/9:30 EDT.

The meeting will take place at Holborn Bars, 138-142 Holborn, London EC1 2NQ.

Please email claire.rowell@fd.com to register to attend this meeting in London.
The details of the conference call are as follows:

UK and International dial in +44-(0)-203-023-4496

US dial in: +1-866-966-5335

Password/Conf ID: Shire

Live Webcast:

The call will also be available live over the Internet via audio webcast, accessible through http://www.shire.com in the investors section. A slide presentation to accompany the call will also be available on the Shire website.

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:

UK and International dial in +44-(0)-208-196-1998

US dial in +1-866-583-1035

Pin code 3008632

Webcast replay: http://www.shire.com, in the investors

section

Notes to Editors

SHIRE LIMITED Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.
For further information please contact:

Investor Relations

Souheil Salah (Rest of the World) +44-1256-894-160

Emily Berish (North America) +1-484-595-8546


'/>"/>
SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... CA (PRWEB) , ... July 20, 2017 , ... Corporate ... governance at its 27th annual Director of the Year Awards. , The awards will ... La Jolla. This annual event celebrates directors who have made significantly positive contributions ...
(Date:7/18/2017)... ... July 18, 2017 , ... Sourcing custom glass or ... needs and has the capabilities to properly execute your job can take many hours ... is a sourcing portal designed to showcase the company’s capabilities and core custom ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... Blood centers ... patients across the region. Nationally, summer is a struggle for community blood centers as ... the San Antonio Chamber of Commerce is teaming up with the ...
(Date:7/17/2017)... ... 17, 2017 , ... Whitehouse Laboratories is excited to announce ... full series of ISO 80369 standard test procedures. The ISO 80369 series of ... delivery systems. With this recent expansion, Whitehouse Labs becomes one of the only ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):